| |
|
|
| |
You are here: Home: BCU 7 | 2005: Kathy D Miller, MD: Select publications
|
|
| |
|
|
| |
|
|
| |
Select publications
Albain KS et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs paclitaxel
(T) as frontline therapy for metastatic breast cancer (MBC): First report of overall
survival. Proc ASCO 2004;Abstract 510.
Burstein HJ et al. Phase II trial of the anti-VEGF antibody bevacizumab in combination
with vinorelbine for refractory advanced breast cancer. San Antonio Breast Cancer
Symposium 2002;Poster 446. Abstract
Miller KD et al. E2100: A randomized phase III trial of paclitaxel versus paclitaxel plus
bevacizumab as f irst-line therapy for locally recurrent or metastatic breast cancer. Presentation. ASCO 2005. No abstract available
Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab
plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23(4):792-9. Abstract
O’Shaughnessy J et al. Superior survival with capecitabine plus docetaxel combination
therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III
trial results. J Clin Oncol 2002;20(12):2812-23. Abstract
Sledge GW et al. Phase III trial of doxorubicin, paclitaxel, and the combination of
doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer:
An intergroup trial (E1193). J Clin Oncol 2003;21(4):588-92. Abstract
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
|
